Molecular genetics and related developments in pancreatic cancer

Current Opinion in Gastroenterology

Volumn 15, Issue 5, 1999, Pages 404-409

  Hruban, Ralph H ^a,b   Goggins, Michael ^a   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; DNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P16; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER SCREENING; DNA REPAIR; FAMILIAL CANCER; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0032814008     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199909000-00006     Document Type: Article

References (72)

1. 1 Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH: The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 1997, 150:383-391.
2. 2 Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32.
3. 3 Day JD, DiGiuseppe JA, Yeo CJ, Loi-Goldman M, Anderson S, Kern SE, Hruban RH: Immunohistochemical evaluation of HER-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996, 27:119-124.
4. 4 DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, et al.: Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994, 101.684-688.
5. 5 DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH: p53-independent expression of the cyclin dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995, 147:884-888.
6. +. Am J Pathol 1998, 152:1501-1507. This paper describes a new type of pancreatic cancer that is associated with a specific genetic abnormality.
7. 7 Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, daCosta LT, Rozenblum E, et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
8. 8 Hruban RH, Petersen GM, Ha PK, Kern SE: Genetics of pancreatic cancer: from genes to families. Surg Oncol Clin N Am 1998, 7:1-23. This is an extensive review on pancreatic cancer.
9. 9 Hruban RH, van Mansfeld ADM, Offerhaus GJA, van Weering DHJ, Allison DC, Goodman SN, et al.: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993, 143:545-554.
10. 10 Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ. Kern SE: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033.
11. 11 Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734.
12. 12 Schutte M, daCosta LT, Hahn SA, Moskaluk CA, Hoque ATMS, Rozenblum E, et al.: Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A 1995, 92:5950-5954.
13. 13 Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130.
14. 14 Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al.: Gene expression profiles in normal and cancer cells. Science 1997. 276:1268-1272.
15. WAF1, and TGF-b1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival. Am J Clin Pathol 1998, 110:16-23.
16. 16 Gansauge S, Schmid RM, Muller J, Adler G, Mattfeld T, Beger HG: Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg 1938, 85:337-340.
17. 17 Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al.: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364.
18. 18 Kommann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M: Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998, 55:363-369.
19. 19 Ohshio G, Suwa H, Imamura T, Yamaki K, Tanaka T, Hashimoto Y, Imamura M: An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol 1998, 33:535-539.
20. 20 Yiwei L, Bhuiyan M, Vaitkevicius VK, Sarkar FH: Molecular analysis of the p53 gene in pancreatic adenocarcinoma. Diagn Mol Pathol 1998, 7:4-9.
21. 21 Lemoine NR: Molecular advances in pancreatic cancer. Digestion 1997, 58:550-556.
22. 22 Goggins M, Shekher M, Kenan T, Yeo CJ, Hruban RH, Kern SE: Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998, 58:5329-5332.
23. 23 Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998, 18:38-43.
24. 24 Su GH, Hilgers W, Shekher M, Tang D, Yeo CJ, Hruban RH, Kern SE: Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. Cancer Res 1998, 58:2339-2342.
25. 25 Su GH, Hruban RH, Bansal RK, Bova GS, Tang DT, Shekher MC, et al.: Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999, 154:1835-1840. This paper shows that the Peutz-Jeghers gene plays a role in the development of pancreatic cancer.
26. 26 Venkatasubbarao K, Ahmed MM, Swiderski C, Harp C, Lee EY, McGarth P, et al.: Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancre atic carcinomas. Genes Chromosom Cancer 1998, 22:138-144.
27. 27 Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al.: Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 1998, 17:1969-1978.
28. 28 Wagner M, Kleeff J, Lopez ME, Bookman I, Massaqué J, Korc M: Transfection of the type 1 TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. Int J Cancer 1998, 78:255-260.
29. 29 Teng DHF, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, et al.: Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997, 57:4177-4182.
30. 30 Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al.: A serine/threonine kinase gene defective in Peutz Jeghers syndrome. Nature 1998, 391:184-187.
31. 31 Hemminki A, Tomlinson I, Markie D. Jarvinen H, Sistonen P, Bjorkqvist AM, et al.: Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997, 15:87-90.
32. 32 Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV, et al.: Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987, 316:1511-1514.
33. 33 Knudson AG: Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985, 45:1437-1443.
34. 34 Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996, 122:135-140.
35. 35 Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996, 93:3636-3641.
36. 36 Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, et al.: Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biomed Biophys Res Commun 1996, 225:968-974.
37. 37 Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR: Amplification and overexpression of the AK12 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 199S, 21:81 -86.
38. 38 Ghadimi BM, Schröck E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T: Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999, 154:525-536.
39. 39 Markowitz S, Wang J, Myeroff L, Parsons R, Sun LZ, Lutterbaugh J, et al.: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
40. 40 Gjertsen MK, Gaudernack G: Mutated ras peptides as vaccines in immunotherapy of cancer. Vox Sang 1998, 74:489-495. This paper describes a novel vaccine that uses mutant K-ras to treat pancreatic cancers.
41. 41 Kita K, Saito S, Morioka CY, Watanabe A: Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated k-ras genes. Int J Cancer 1999, 80:553-558.
42. 42 Müller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, Koch OM: Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type k-ras oncogene has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998, 12:717-723. This new class of drugs may be useful in the treatment of pancreatic cancer.
43. 43 Friess H, Kleef J, Gumbs A, Büchler MW: Molecular versus conventional markers in pancreatic cancer. Digestion 1997, 58:557-563.
44. 44 Hrubao RH, van der Riel P, Erozan Y, Sidransky D: Molecular biology and the early detection of carcinoma of the bladder the case of Hubert H. Humphrey. N Engl J Med 1994, 330:1276-1278.
45. 45 Berndt C, Haubold K, Wenger F, Brux B, Müller J, Bendzko P, el al.: K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998, 44:2103-2107.
46. 46 Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994, 54:3568-3573.
47. 47 Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD: Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17:89-97.
48. 48 Ochi K, Hasuoka H, Mizushima T, Matsumura N, Harada H: A case of small pancreatic cancer diagnosed by serial follow-up studies promptly by a positive K-ras point mutation in pure pancreatic juice. Am J Gastroenterol 1998, 93:1366-1368.
49. 49 Shibata K, Mori M, Kitano S, Akiyoshi T: Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification. Int J Oncol 1998, 12:1333-1338.
50. 50 Iada M, Ieratani T, Komatsu Y, Kawabe T, Shiratori Y, Omata M: Quantitative analysis of ras gene mutation in pancreatic juice for diagnosis of pancreatic adenocarcinoma. Dig Dis Sci 1998, 43:15-20.
51. 51 Wilentz RE, Chung CH, Sturm PDJ, Musler A, Sohn TA, Offerhaus GJA, et al.: K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998, 82:96-103.
52. 52 Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, et al.: Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998, 4:1527-1532.
53. 53 Fukushige S, Furukawa T, Satoh K, Sunamura M, Koizumi M, Horii A: Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res 1998, 58:4223-4226.
54. 54 Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, et al.: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997, 57:326-331.
55. 55 Iwao I, Hiyama E, Yokoyama T, Tsuchida A, Hiyama K, Murakami Y, et al.: Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 1997, 89:1621 -1623.
56. 56 Shay JW, Gazdar AF: Telomerase in the early detection of cancer. J Clin Pathol 1997, 50:106-109.
57. 57 Suehara N, Mizumoto K, Kusumoto M, Niiyama H, Ogawa T, Yamaguchi K, et al.: Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am J Gastroenterol 1997, 93:1967-1971.
58. 58 Tsutsumi M, Tsujiuchi T, Ishikawa O, Majima T, Yoshimoto T, Sasaki Y, et al.: Increased telomerase activities in human pancreatic duct adenocarcinomas. Jpn J Cancer Res 1997, 88:971-976.
59. 59 Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science 1995, 270:484-487.
60. 60 Zhou W, Sokoll LJ, Bruzek DJ, Zhang L, Velculescu VE, Goldin SB, et al.: Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998, 7:109-112. This paper demonstrates the development of a new screening test for pancreatic cancer that uses serial analysis of gene expression.
61. 61 Hruban RH, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJA, Falatko F, Kern SE: Familial pancreatic cancer. Ann Oncol 1999, in press.
62. 62 Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al.: Familial pancreatic cancer: a review. Semin Oncol 1996, 23:251-275.
63. 63 Bartsch D, Bastian D, Barth P, Schudy A, Nies C, Kisker C, et al.: K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann Surg 1998, 228:79-86.
64. 64 Fukushima N, Suzuki M, Fukayama M; Analysis of K-ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juice. Pathol Int 1998, 48:33-40.
65. 65 Jaffce EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, et al.: Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998, 4:194-203. This paper describes the development of an exciting new vaccine for the treatment of pancreatic cancer.
66. 66 Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E, et al.: K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits. Clin Chem 1998, 44:2243-2248.
67. 67 Westra WH, Sturm PJ, Drillenburg P, Choti MA, Klimstra DS, Abores-Saavedra J, et al.: K-ras oncogene mutations in osteoclast-like giant-cell tumors of the pancreas and liver; genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 1998, 22:1247-1254.
68. 68 Yamashita K, Kuba T, Shinoda H, Takahashi E, Okayasu I: Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998, 109:704-711.
69. 69 Sturm PDJ, Hruban RH, Ramsoekh TB, Noorduyn LA, Tytgat GNJ, Gouma DJ, Offerhaus GJA: The potential diagnostic use of k-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998, 186:247-253.
70. 70 Jaffee EM; A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998, 9:1951-1971.
71. 71 Abbott DW, Freeman ML, Holt, JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998, 90:978-985. This article suggests that cancers with BRCA2 mutations may be more sensitive to radiation.
72. 72 Ozcelik H, Schmocker B, DiNicola N, Shi XH, Langer B, Moore M, et al.: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16:17-18.